S

Sanofi

Global pharma company; vaccines and R&D

Team Lead GRA Labelling Strategist

Full-TimeUpdated on 10/24/2026Deadline 10/31/26
No salary listed
Expert
Bachelor's, Master's, MD
Hyderabad, Telangana, India
HybridHybrid model.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Knowledge of regulatory and labeling requirements in major markets for marketing authorization filings for new products or updates to marketed products, and knowledge of Labeling Team purpose and objectives.
  • Strong knowledge of drug labeling requirements, including CCDS, EU and US guidance and regulations, and drug-device combinations; ability to coordinate discussions across company levels and reach resolution on labeling topics.
  • Knowledge of US and EU regulations and the general international regulatory environment.
  • Ability to train and mentor junior Labeling team members on CCDS, EU and US guidance and regulations, and strategies for implementing them in labeling text.
  • Ability to read and interpret health authority regulations and guidance, and relevant company standard operating procedures.
  • Proven ability to lead labeling strategy and guide a team of labeling strategists in alignment with regulatory strategy.
  • Ability to lead matrix teams, manage up, negotiate, and build consensus on complex topics.
  • Ability to work autonomously on most topics, seek feedback on highly complex topics, and provide oversight to direct reports.
  • Ability to lead multidisciplinary labeling working groups involving Global Regulatory Affairs, Global Pharmacovigilance, Global Medical Affairs, Legal, preclinical, and Chemistry, Manufacturing, and Controls; develop labeling strategy proposals, negotiate, resolve conflict, and build consensus.
  • Ability to support local countries as a global labeling subject-matter expert during labeling negotiations and health authority discussions.
  • Ability to construct company responses to EU and US health authority questions related to labeling.
  • Knowledge of end-to-end labeling processes and interfaces among Regulatory, Medical Affairs, Pharmacovigilance, and Quality.
  • At least 10 years of relevant experience.
  • At least 3 years of people-management experience for individuals in the managerial track.
  • Experience executing training plans, assessing competency, and closing individual training gaps through targeted development.
  • Experience conducting team performance management, including goal setting, feedback, and coaching.
  • Ability to assign and balance product responsibility across a team based on capacity and skill level.
  • Strong written and verbal communication and networking skills.
  • Situational awareness, leadership, and problem-solving skills.
  • Ability to work with associates and direct management at all company levels, domestically and internationally, with communication, interpersonal, and organizational skills.
  • Strong attention to detail, analytical and organizational skills, project management skills, critical thinking, self-direction, and ability to coordinate discussions across company levels to resolve labeling topics.
  • Ability to build or learn scientific knowledge, such as statistics and disease-area knowledge, to improve agility across therapeutic areas.
  • Ability to search for public data on labeling elements and regulatory strategy using digital capabilities.
  • Ability to manage projects and people and document progress and outcomes for assigned product and people portfolios.
  • Familiarity with labeling and document management systems, including Veeva Vault, EDMS, RIM systems, and text verification and quality-control tools.
  • Education as a physician, pharmacist, veterinarian, or bachelor's degree in Life Sciences.
  • Fluent business English.
Responsibilities
  • Define and lead labeling strategy to create or update corporate labeling documents (CCDS, US, EU, WHO) and corresponding patient leaflets for development projects and lifecycle-management or marketed products, including text for proposed labeling for new indications, within regulatory submissions for new or updated marketing authorizations and company or agency approval.
  • Coordinate labeling review and approval throughout the end-to-end labeling process, including preparing labeling components for regulatory submissions, participating in agency labeling negotiations that result in product approvals or updates, and releasing labeling for company use across development, marketed, and lifecycle-management products, including complex updates, line extensions, and new indications.
  • Support cross-functional teams as a labeling expert within GRAL, GRT, and GRA; contribute to global regulatory strategies and prepare labeling components of submission dossiers or responses to health authorities.
  • Chair multidisciplinary labeling working groups, present labeling proposals, develop consensus, and present proposals to the Labeling Governance Committee for internal approval.
  • Provide oversight for the team and assigned products, and provide strategic guidance and project training, including review and validation of labeling proposals as needed; inform management as necessary.
  • Serve on response teams for EU and US procedures, including complex matters such as European arbitrations or referrals, work-sharing, PRAC questions, signal detection, labeling negotiations, and urgent safety restrictions, supporting the maintenance and compliance of existing marketing authorizations.
  • Anticipate implementation hurdles, act to minimize them, and inform management as needed.
  • Coordinate, create, and present labeling proposals to senior executive management through the Labeling Review Committee.
  • Assess relevant study reports, post-marketing pharmacovigilance data, and other scientific reports needed to support labeling proposals.
  • Perform labeling competitive and comparator analyses to provide expert-level insights.
  • Meet established submission timelines and quality standards for labeling deliverables.
  • Provide team training and mentoring on CCDS, EU, and US guidance and regulations and strategies for implementing them in labeling text.
  • Lead and support cross-functional or process-improvement workstreams and projects.
  • Execute training plans, assess team members' competency, and close individual training gaps through targeted development.
  • Conduct team performance management, including goal setting, feedback, and coaching.
  • Assign and balance product responsibility across the team based on capacity and skill level.
  • Manage resource planning and coverage for vacations, turnover, sick leave, and peak workloads without disrupting deliverables.
  • Ensure product and project coverage within the group, identify gaps and resource constraints, and implement solutions for presentation to management.
  • Forecast capacity against portfolio demand and reallocate work when gaps emerge.
Desired Qualifications
  • An advanced degree is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...